Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9BXR0

UPID:
TGT_HUMAN

ALTERNATIVE NAMES:
Guanine insertion enzyme; tRNA-guanine transglycosylase

ALTERNATIVE UPACC:
Q9BXR0; B4DFM7; Q96BQ4; Q9BXQ9

BACKGROUND:
The enzyme Queuine tRNA-ribosyltransferase catalytic subunit 1, recognized alternatively as Guanine insertion enzyme or tRNA-guanine transglycosylase, is essential for tRNA modification. By exchanging guanine with queuine at the anticodon wobble position, it ensures the synthesis of queuosine, a modification vital for the fidelity of protein synthesis. This process is key to maintaining the efficiency and accuracy of the genetic code translation.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Queuine tRNA-ribosyltransferase catalytic subunit 1 offers a promising avenue for the development of novel therapeutic approaches. Given its central role in protein synthesis, targeting this enzyme could lead to innovative treatments that precisely regulate gene expression in disease contexts.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.